Novartis: Data Support Superiority Of Tasigna Over Glivec

Swiss drugmaker Novartis AG (NVS) said findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna or nilotinib compared to Glivec or imatinib at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia or Ph+ CML patient populations.

These populations include newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec.

Tasigna is approved in over 110 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Glivec.

These results were presented in oral sessions at the 55th annual meeting of the American Society of Hematology or ASH in New Orleans. They add to the growing body of evidence confirming the superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients, Novartis noted.

The five-year ENESTnd data presented continued to support the use of Tasigna in newly diagnosed Ph+ CML patients and demonstrated higher rates of early and deeper sustained molecular response, including MR4.5, and a reduced risk of progression compared to Glivec.

ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna compared to Glivec.

A separate study, ENESTcmr, confirmed that treatment with Tasigna led to deeper molecular response in patients who switch after long-term treatment with Glivec.

New data showed that patients who failed to respond to frontline Glivec achieved higher rates of molecular response with switch to Tasigna in comparison with Glivec dose escalation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Restaurant Association or NRA has urged the U.S. Congress to refill the Restaurant Revitalization Fund or RRF, which is expected to save more than 1.6 million jobs in the restaurant industry hit hard by the surge in Omicron Variant. In a letter to Congress, the association highlighted, based on its survey on 4,200 restaurant operators, the devastating impact so far on the industry... Industrial conglomerate General Electric Co. reported Tuesday a net loss for the fourth quarter compared to a profit last year, hurt by steep debt extinguishment costs and lower revenues. However, adjusted earnings per share topped analysts' expectations, while quarterly revenues missed them. Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin.
Follow RTT